Each 5-point reduction in LVEF increased the risk of cardiovascular death or HF hospitalization by 9% (HR 1.09; 95% CI 1.05-1.13; P<0.001), with sacubitril/valsartan effective across the LVEF spectrum.
RCT (n=8,399)
Yes
Does sacubitril/valsartan reduce cardiovascular death or HF hospitalization across the LVEF spectrum in patients with HFrEF compared to enalapril?
Sacubitril/valsartan is consistently effective at reducing cardiovascular death and heart failure hospitalization across the entire spectrum of reduced ejection fraction (≤40%).
Effect estimate: HR 1.09 (95% CI 1.05-1.13)
p-value: p=<0.001
BACKGROUND: The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with enalapril in patients with heart failure (HF) and reduced ejection fraction (EF) in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. We evaluated the influence of EF on clinical outcomes and on the effectiveness of sacubitril/valsartan compared with enalapril. METHODS AND RESULTS: Eight thousand three hundred ninety-nine patients with New York Heart Association class II to IV HF with reduced EF left ventricular EF (LVEF) ≤40% were randomized to sacubitril/valsartan 97/103 mg twice daily versus enalapril 10 mg twice daily and followed for a median of 27 months. The primary study end point was cardiovascular death or HF hospitalization. LVEF was assessed at the sites and recorded on case report forms. We related LVEF to study outcomes and assessed the effectiveness of sacubitril/valsartan across the LVEF spectrum. The mean LVEF in PARADIGM-HF, reported by sites, was 29.5 (interquartile range, 25-34). The risk of all outcomes increased with decreasing LVEF. Each 5-point reduction in LVEF was associated with a 9% increased risk of cardiovascular death or HF hospitalization (hazard ratio, 1.09; 95% confidence interval, 1.05-1.13; P<0.001), a 9% increased risk for CV death (hazard ratio, 1.09; 95% confidence interval, 1.04-1.14), a 9% increased risk in HF hospitalization (hazard ratio, 1.09; 95% confidence interval, 1.04-1.14) and a 7% increased risk in all-cause mortality (hazard ratio, 1.07; 95% confidence interval, 1.03-1.12) in adjusted analyses. Sacubitril/valsartan was effective across the LVEF spectrum, with no evidence of heterogeneity, when modeled either in tertiles (P interaction=0.87) or continuously (P interaction=0.95). CONCLUSIONS: In patients with HF and reduced EF enrolled in PARADIGM-HF, LVEF was a significant and independent predictor of all outcomes. Sacubitril/valsartan was effective at reducing cardiovascular death and HF hospitalization throughout the LVEF spectrum. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.
Solomon et al. (2016) conducted an RCT in Heart failure with reduced ejection fraction (n=8,399). Sacubitril/valsartan vs. Enalapril 10 mg twice daily was evaluated on Cardiovascular death or HF hospitalization (HR 1.09, 95% CI 1.05-1.13, p=<0.001). Each 5-point reduction in LVEF increased the risk of cardiovascular death or HF hospitalization by 9% (HR 1.09; 95% CI 1.05-1.13; P<0.001), with sacubitril/valsartan effective across the LVEF spectrum.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: